Skip to main content
Clinical Trials/JPRN-jRCTs051230072
JPRN-jRCTs051230072
Recruiting
Phase 3

For postoperative body fluid management and postoperative complication prevention Torbaptan's effectiveness

Esaki Jiro0 sites200 target enrollmentJuly 20, 2023

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Patients receiving Open Heart Surgery
Sponsor
Esaki Jiro
Enrollment
200
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 20, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Esaki Jiro

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients planning to perform open heart surgery under a heart\-lung machine
  • 2\) Patients who are aged 20 or older when acquiring consent
  • 3\) Patients who have obtained document consent with their own freedom after fully understood participation in this research

Exclusion Criteria

  • 1\)Patients who underwent emergency surgery
  • 2\)Patients with a history of hypersensitivity to tolvaptan components or similar
  • compounds (such as mozavaptan hydrochloride)
  • 3\)Patients receiving desmopressin acetate hydrate (nocturia due to nocturia in men)
  • 4\)Patients with a history of hypersensitivity to sulfonamide derivatives
  • 5\)Patients with heart failure and markedly decreased EF (EF\<30%)
  • 6\)Patients with chronic renal dysfunction on dialysis
  • 7\)Patients with liver cirrhosis
  • 8\)Patients who underwent thoracoabdominal aortic replacement or heart\-beating coronary artery bypass surgery alone
  • 9\)Patients who are already using tolvaptan including oral medicines and injections at

Outcomes

Primary Outcomes

Not specified

Similar Trials